&Partners Makes New $783,000 Investment in Novo Nordisk A/S (NYSE:NVO)

&Partners purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,100 shares of the company’s stock, valued at approximately $783,000.

Other large investors have also recently made changes to their positions in the company. Pacific Center for Financial Services grew its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the period. CNB Bank bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $26,000. Tyler Stone Wealth Management grew its position in Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the period. West Paces Advisors Inc. increased its holdings in Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the last quarter. Finally, Valued Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the fourth quarter worth approximately $28,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NVO opened at $141.96 on Monday. The firm has a market cap of $637.05 billion, a P/E ratio of 48.95, a PEG ratio of 1.40 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $144.50. The company has a 50 day simple moving average of $132.94 and a two-hundred day simple moving average of $122.05. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Equities analysts forecast that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Argus boosted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target for the company. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.